6.
Moore H, Unger J, Phillips K, Boyle F, Hitre E, Porter D
. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372(10):923-32.
PMC: 4405231.
DOI: 10.1056/NEJMoa1413204.
View
7.
Liu T, Liu C, Yan M, Zhang L, Zhang J, Xiao M
. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients. Nat Commun. 2022; 13(1):6823.
PMC: 9649678.
DOI: 10.1038/s41467-022-34581-2.
View
8.
Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J
. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019; 30(8):1289-1297.
DOI: 10.1093/annonc/mdz177.
View
9.
Kumar T, Hobbs E, Yang F, Chang J, Contreras A, Parra Cuentas E
. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022; 28(17):3669-3676.
PMC: 9444971.
DOI: 10.1158/1078-0432.CCR-21-1278.
View
10.
Ambrosone C, Zirpoli G, Hutson A, McCann W, McCann S, Barlow W
. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2019; 38(8):804-814.
PMC: 7062457.
DOI: 10.1200/JCO.19.01203.
View
11.
Perez-Garcia J, Gebhart G, Borrego M, Stradella A, Bermejo B, Schmid P
. Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021; 22(6):858-871.
DOI: 10.1016/S1470-2045(21)00122-4.
View
12.
Wang C, Lutes L, Barnoud C, Scheiermann C
. The circadian immune system. Sci Immunol. 2022; 7(72):eabm2465.
DOI: 10.1126/sciimmunol.abm2465.
View
13.
Benitez S, Cordero A, Santamaria P, Redondo-Pedraza J, Rocha A, Collado-Sole A
. RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. Dev Cell. 2021; 56(12):1727-1741.e7.
PMC: 8221814.
DOI: 10.1016/j.devcel.2021.04.022.
View
14.
Min J, Im H, Allen M, McFarland P, Degani I, Yu H
. Computational Optics Enables Breast Cancer Profiling in Point-of-Care Settings. ACS Nano. 2018; 12(9):9081-9090.
PMC: 6519708.
DOI: 10.1021/acsnano.8b03029.
View
15.
Shen Y, E Shamout F, Oliver J, Witowski J, Kannan K, Park J
. Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams. Nat Commun. 2021; 12(1):5645.
PMC: 8463596.
DOI: 10.1038/s41467-021-26023-2.
View
16.
Risson E, Nobre A, Maguer-Satta V, Aguirre-Ghiso J
. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2021; 1(7):672-680.
PMC: 7929485.
DOI: 10.1038/s43018-020-0088-5.
View
17.
Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D
. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4.
PMC: 3428862.
DOI: 10.1038/nature11017.
View
18.
Giuliano A, Ballman K, McCall L, Beitsch P, Brennan M, Kelemen P
. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017; 318(10):918-926.
PMC: 5672806.
DOI: 10.1001/jama.2017.11470.
View
19.
Li J, Wang D, Zhao Y, Zhou J, Tang J
. Clinical assessment of magnetic resonance imaging-guided radiofrequency ablation for breast cancer. Mol Clin Oncol. 2019; 11(4):411-415.
PMC: 6713947.
DOI: 10.3892/mco.2019.1905.
View
20.
Kunkler I, Williams L, Jack W, Cameron D, Dixon J
. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N Engl J Med. 2023; 388(7):585-594.
DOI: 10.1056/NEJMoa2207586.
View